Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) Gross Margin (2018 - 2026)

TransMedics has reported Gross Margin over the past 8 years, most recently at 58.11% for Q4 2025.

  • For Q4 2025, Gross Margin fell 110.0% year-over-year to 58.11%; the TTM value through Dec 2025 reached 59.92%, up 56.0%, while the annual FY2025 figure was 59.92%, 56.0% up from the prior year.
  • Gross Margin for Q4 2025 was 58.11% at TransMedics, down from 58.8% in the prior quarter.
  • Over five years, Gross Margin peaked at 81.76% in Q4 2021 and troughed at 55.94% in Q3 2024.
  • A 5-year average of 65.38% and a median of 63.95% in 2022 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: skyrocketed 1974bps in 2021 and later tumbled -1577bps in 2022.
  • Year by year, Gross Margin stood at 81.76% in 2021, then dropped by -19bps to 65.99% in 2022, then decreased by -11bps to 59.04% in 2023, then rose by 0bps to 59.21% in 2024, then dropped by -2bps to 58.11% in 2025.
  • Business Quant data shows Gross Margin for TMDX at 58.11% in Q4 2025, 58.8% in Q3 2025, and 61.38% in Q2 2025.